Daniel Cohen - Pharnext Director
| ALPHA Stock | EUR 0.0002 0.00 0.00% |
Insider
Daniel Cohen is Director of Pharnext SA
| Age | 70 |
| Phone | 33 1 41 09 22 30 |
| Web | https://www.pharnext.com |
Daniel Cohen Latest Insider Activity
Tracking and analyzing the buying and selling activities of Daniel Cohen against Pharnext stock is an integral part of due diligence when investing in Pharnext. Daniel Cohen insider activity provides valuable insight into whether Pharnext is net buyers or sellers over its current business cycle. Note, Pharnext insiders must abide by specific rules, including filing SEC forms every time they buy or sell Pharnext'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Daniel Cohen over three weeks ago Disposition of 15000 shares by Daniel Cohen of Cohen subject to Rule 16b-3 | ||
Daniel Cohen over two months ago Acquisition by Daniel Cohen of 2000000 shares of Cohen subject to Rule 16b-3 | ||
Daniel Cohen over six months ago Disposition of 20000 shares by Daniel Cohen of Cohen subject to Rule 16b-3 | ||
Daniel Cohen over six months ago Disposition of 15000 shares by Daniel Cohen of Cohen subject to Rule 16b-3 |
Pharnext Management Efficiency
The company has return on total asset (ROA) of (0.7578) % which means that it has lost $0.7578 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (13.4844) %, meaning that it generated substantial loss on money invested by shareholders. Pharnext's management efficiency ratios could be used to measure how well Pharnext manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Kathryn McNeil | Nanobiotix SA | 48 | |
| Alexis BERNARD | AB Science SA | N/A | |
| Alain MBA | AB Science SA | N/A | |
| Sarah Gaubert | Nanobiotix SA | N/A | |
| Marc Bonneville | Innate Pharma | 63 | |
| Pascal Prigent | Genfit | 55 | |
| Frederic MBA | Innate Pharma | 48 | |
| Thomas Baetz | Genfit | 49 | |
| Yves MD | AB Science SA | N/A | |
| Pascal Caisey | Genfit | 55 | |
| Albert DVM | AB Science SA | N/A | |
| Emilie Desodt | Genfit | 40 | |
| Earl Bergey | Nanobiotix SA | 68 | |
| Laurent Levy | Nanobiotix SA | 50 | |
| Laurent Lannoo | Genfit | 53 | |
| Bart Rhijn | Nanobiotix SA | N/A | |
| Odile Belzunce | Innate Pharma | 43 | |
| Christian FASSOTTE | AB Science SA | N/A | |
| Alessandro MD | Innate Pharma | N/A | |
| DVM MBA | Innate Pharma | 58 | |
| Franois Romagn | Innate Pharma | 59 | |
Management Performance
| Return On Equity | -13.48 | |||
| Return On Asset | -0.76 |
Pharnext SA Leadership Team
Elected by the shareholders, the Pharnext's board of directors comprises two types of representatives: Pharnext inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pharnext. The board's role is to monitor Pharnext's management team and ensure that shareholders' interests are well served. Pharnext's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pharnext's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joshua Schafer, Interim Chairman | ||
| Xavier MSc, Chief Officer | ||
| Rodolphe Hajj, Chief Officer | ||
| Susanne Dorn, Chief Officer | ||
| Daniel Cohen, Director | ||
| DSc Chumakov, Chairman CoFounder | ||
| Rob Quinn, Chief Officer | ||
| Philippe Rinaudo, Chief Officer | ||
| David MD, CEO Director | ||
| Antoine Gravelle, G Counsel | ||
| Viviane Bertrand, Chief Officer |
Pharnext Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pharnext a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -13.48 | |||
| Return On Asset | -0.76 | |||
| Operating Margin | (9.13) % | |||
| Current Valuation | 20.06 M | |||
| Shares Outstanding | 875.25 M | |||
| Shares Owned By Insiders | 0.68 % | |||
| Shares Owned By Institutions | 0.04 % | |||
| Price To Book | 24.54 X | |||
| Price To Sales | 0.1 X | |||
| Revenue | 84.78 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Additional Tools for Pharnext Stock Analysis
When running Pharnext's price analysis, check to measure Pharnext's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharnext is operating at the current time. Most of Pharnext's value examination focuses on studying past and present price action to predict the probability of Pharnext's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharnext's price. Additionally, you may evaluate how the addition of Pharnext to your portfolios can decrease your overall portfolio volatility.